Finally, it has been suggested that pharmacological inhibition of histone H3K9 demethylase, either alone or in combination with MAPKi, and co-targeting of EZH2 together with one of its regulators, NFATc2, may benefit the treatment of resistant BRAF V600E melanomas [120,121]. Here, BRAF is linked to melanoma.